research use only
Cat.No.S2374
|
In vitro |
DMSO
: 44 mg/mL
(199.8 mM)
Water : 7 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 220.22 | Formula | C11H12N2O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 56-69-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC-92523 | SMILES | C1=CC2=C(C=C1O)C(=CN2)CC(C(=O)O)N | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
5-Hydroxytryptophan (5-HTP) is the intermediate metabolite of the essential amino acid L-tryptophan (LT) in the biosynthesis of serotonin. It easily crosses the blood-brain barrier and effectively increases central nervous system (CNS) synthesis of serotonin. Therapeutic administration of this compound has been shown to be effective in treating a wide variety of conditions, including depression, fibromyalgia, binge eating associated with obesity, chronic headaches, and insomnia. Clinical available evidence suggests it is better than placebo at alleviating depression.
|
|---|---|
| In vivo |
LD50 of 5-hydroxytryptophan (5-HTP): Mice 1800mg/kg (i.g.); Rats 300mg/kg (i.g.)
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-08-27)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05895747 | RECRUITING | Major Depressive Disorder |
University of Utah |
2023-09-28 | PHASE2 |
| NCT07777328 | RECRUITING | Attention Deficit and Hyperactivity Disorder (ADHD); Attention Deficit Hyperactivity Disorder in Adults; Attention Deficits |
University of Sheffield |
2025-11-25 | |
| NCT06718452 | NOT_YET_RECRUITING | Tinnitus; Neuroinflammation |
University of Campania Luigi Vanvitelli |
2026-04-20 | |
| NCT04520178 | RECRUITING | Spinal Cord Injuries |
University of Alberta |
2020-07-01 | PHASE2; PHASE3 |
| NCT04160910 | RECRUITING | Mild or Moderate Asthma With Allergic Sensitization |
Indiana University |
2021-02-11 | PHASE2 |
| NCT04395183 | COMPLETED | Major Depressive Disorder |
University of Utah |
2021-03-01 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.